Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
The company has also started working with a large pharma company on the API supply of a recently launched animal and human health product
The company has has 10 existing labs in India
The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
The Indian Pharmacopoeia Commission (IPC) has added 23 new impurities standards and 7 new Indian Pharmacopoeial Reference standards
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead
Amptron’s R &D is based out of the US and this will enable Max to obtain US and other global certifications. Max will retain the right to market, sell and distribute the products in India.
Subscribe To Our Newsletter & Stay Updated
